MC1R and melanoma: Millions of individuals stand to benefit from this strategy, particularly those expressing mutations in other skin cancer or melanoma susceptibility genes (e.g., CDKN2A), and those heterozygous for MC1R RHC variants, who represent 50% of the entire white population in the U.S.A. [124].